Related Experiment Videos
[Clinical evaluation of cefoxitin in children (author's transl)]
Insights
Cefoxitin (CFX) is a safe and effective antibiotic for treating bacterial infections in children. Studies show it successfully cured all 10 pediatric patients with susceptible bacterial infections.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and pharmacokinetics
- Antibiotic efficacy and safety
Context:
- Cefoxitin (CFX) is a cephalosporin antibiotic.
- Pediatric infections require effective and safe treatment options.
- Understanding antibiotic pharmacokinetics is crucial for pediatric dosing.
Purpose:
- To evaluate the safety and efficacy of Cefoxitin (CFX) in pediatric patients.
- To assess the pharmacokinetic profile of Cefoxitin (CFX) in children.
- To determine the susceptibility of common pediatric bacterial pathogens to Cefoxitin (CFX).
Summary:
- Fifteen pediatric patients received Cefoxitin (CFX) intravenously (73-125 mg/kg/day) for various infections.
- All 10 patients with bacterial infections (e.g., S. pyogenes, S. pneumoniae, E. coli) were cured.
- Adverse effects included mild diarrhea and transient neutropenia; Cefoxitin demonstrated good penetration into cerebrospinal fluid.
Impact:
- Cefoxitin (CFX) is a viable therapeutic option for susceptible bacterial infections in pediatric populations.
- The study highlights the safety profile and effectiveness of Cefoxitin (CFX) in children.
- Rapid excretion and short half-life necessitate careful consideration in treatment regimens.
Abstract:
Cefoxitin (CFX) was evaluated for its safety and efficacy in children. Fifteen patients were treated with 73-125 mg/kg per day of CFX by intravenous administrations. The diagnosis of the patients were acute pharyngitis (4), pneumonia (2), pertussis and pneumonia (1), urinary tract infection (3); and the remaining 5 patients were esteemed to have nonbacterial infections. All the 10 patients of bacterial infections were cured after the CFX therapy. The pathogens recovered were Streptococcus pyogenes (1), Streptococcus pneumoniae (3), Haemophilus influenzae (2), Escherichia coli (2), enteropathogenic Escherichia coli (1), and Klebsiella pneumoniae (1). All the strains isolated were susceptible to CFX, but the 2 isolates of Haemophilus influenzae had relatively high MIC values (12.5 mcg/ml). Diarrhea (3 cases) and transient neutropenia (1 case) were found to be associated with the CFX therapy. However, no severe adverse reactions were encountered. Half-life of the serum level was short (24.1 minutes) and excretion into the urine was rapid. CSF concentration obtained 30 minutes after an intravenous injection of 50 mg/kg of CFX in 1 case with inflamed meninges was considerably high (8.3 mcg/ml). CFX appears to be a safe and effective antibiotic when used in children with susceptible bacterial infections.